Business
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharma
About this update from Nexentis Technologies Inc.
[{"type":"image","alt":"Nexentis Technologies Inc.","displaySize":"","headline":null,"caption":"Nexentis Technologies Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":87,"url":"https://media.zenfs.com/en/globenewswire.com/0ee5f77b6a25c8fd76a0d391fab68b90"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k6_xVoCzr5NE_UzJNBCsgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/0ee5f77b6a25c8fd76a0d391fab68b90","width":300,"height":87},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/k6_xVoCzr5NE_UzJNBCsgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyMg--/https://media.zenfs.com/en/globenewswire.com/0ee5f77b6a25c8fd76a0d391fab68b90","width":300,"height":87}},"lazy":false},{"type":"text","content":"Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaceutical properties compared to the program's initial hit compound.","length":601,"tagName":"p"},{"type":"text","content":"This milestone represents a pivotal inflection point in MitoCareX's drug discovery program, demonstrating that the Company's proprietary MITOLINE® algorithm platform can power a drug discovery and development progression in a target class that has historically been difficult to drug. MITOLINE® - the U.S. trademark-registered algorithm whose registration was announced by Nexentis in May 2026 enabled the identification of the program's initial hit molecule by generating reliable 3D structural models of a mitochondrial carrier protein in the SLC25 family, overcoming a central bottleneck in mitochondrial drug discovery: the near-total absence of experimentally solved 3D structures for this important protein class. The initial hit was identified by MITOLINE®-enabled virtual screenings and has now undergone systematic medicinal chemistry optimization, culminating in the generation of an optimized hit molecule that demonstrates clear im...